Fig. 4From: Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysisAssessment of publication bias; A Funnel plot analysis; B Meta-regression analysisBack to article page
